Advised a biotechnology unicorn on an aborted acquisition valued at US$ 35 million

Collyer Law advised an American Biotechnology unicorn, specializing in gene therapy, on an aborted acquisition of a Singapore-Based Biotechnology company. The target company, which holds manufacturing operations and assets valued at approximately USD 35 million, was being considered for strategic acquisition to expand the American Biotechnology unicorn's capabilities in specific areas. The transaction involved complex cross-border elements, requiring careful legal and regulatory consideration before the decision to abort was made.